MIRAMAR, Fla., July 15, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NuGenerex IO), today announced the closing of a $50 Million equity financing facility to support the company’s strategic and development plans. NuGenerex IO is now a public company, and once the S1 registration for this $50 Million is filed, and a subsequent S1 for an equity raise is filed in collaboration with its investment bank, the company plans to immediately apply for a listing on either the Nasdaq or NY Stock exchanges. The requisite 8k on this closing will be filed accordingly.

About NuGenerex Immuno-Oncology

NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines for cancer and infectious disease based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda®) for the treatment of triple negative breast cancer. The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.